Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial

被引：148

作者：

Singh, Jagdeep S. S. ^{[1
]}

Mordi, Ify R. ^{[1
]}

Vickneson, Keeran ^{[1
]}

Fathi, Amir ^{[1
]}

Donnan, Peter T. ^{[2
]}

Mohan, Mohapradeep ^{[1
]}

Choy, Anna Maria J. ^{[1
]}

Gandy, Stephen ^{[3
]}

George, Jacob ^{[1
]}

Khan, Faisel ^{[1
]}

Pearson, Ewan R. ^{[2
]}

Houston, J. Graeme ^{[1
]}

Struthers, Allan D. ^{[1
]}

Lang, Chim C. ^{[1
]}

机构：

[1] Univ Dundee, Sch Med, Div Mol & Clin Med, Dundee, Scotland

[2] Univ Dundee, Sch Med, Div Populat Hlth & Genom, Dundee, Scotland

[3] NHS Tayside, Dept Med Phys, Dundee, Scotland

来源：

DIABETES CARE | 2020年 / 43卷 / 06期

基金：

英国医学研究理事会;

关键词：

D O I：

10.2337/dc19-2187

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OBJECTIVE To determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI. RESEARCH DESIGN AND METHODS We randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters. RESULTS In our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight. CONCLUSIONS We were unable to determine with certainty whether dapagliflozin in patients with T2DM and HF had any effect on LV remodeling. Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown.

引用

页码：1356 / 1359

页数：4

共 12 条

[1] Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes [J].

Ferrannini, Ele ;

Baldi, Simona ;

Frascerra, Silvia ;

Astiarraga, Brenno ;

Barsotti, Elisabetta ;

Clerico, Aldo ;

Muscelli, Elza .

DIABETES CARE, 2017, 40 (06) :771-776

[2] Left Ventricular Remodeling in Heart Failure Current Concepts in Clinical Significance and Assessment [J].

Konstam, Marvin A. ;

Kramer, Daniel G. ;

Patel, Ayan R. ;

Maron, Martin S. ;

Udelson, James E. .

JACC-CARDIOVASCULAR IMAGING, 2011, 4 (01) :98-108

[3] Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction A Meta-Analytic Approach [J].

Kramer, Daniel G. ;

Trikalinos, Thomas A. ;

Kent, David M. ;

Antonopoulos, George V. ;

Konstam, Marvin A. ;

Udelson, James E. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (05) :392-406

[4] SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects [J].

Lam, Carolyn S. P. ;

Chandramouli, Chanchal ;

Ahooja, Vineeta ;

Verma, Subodh .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (20)

[5] Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease [J].

Mazer, C. David ;

Hare, Gregory M. T. ;

Connelly, Philip W. ;

Gilbert, Richard E. ;

Shehata, Nadine ;

Quan, Adrian ;

Teoh, Hwee ;

Leiter, Lawrence A. ;

Zinman, Bernard ;

Juni, Peter ;

Zuo, Fei ;

Mistry, Nikhil ;

Thorpe, Kevin E. ;

Goldenberg, Ronald M. ;

Yan, Andrew T. ;

Connelly, Kim A. ;

Verma, Subodh .

CIRCULATION, 2020, 141 (08) :704-707

[6] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [J].

McMurray, J. J. V. ;

Solomon, S. D. ;

Inzucchi, S. E. ;

Kober, L. ;

Kosiborod, M. N. ;

Martinez, F. A. ;

Ponikowski, P. ;

Sabatine, M. S. ;

Anand, I. S. ;

Belohlavek, J. ;

Bohm, M. ;

Chiang, C. -E. ;

Chopra, V. K. ;

de Boer, R. A. ;

Desai, A. S. ;

Diez, M. ;

Drozdz, J. ;

Dukat, A. ;

Ge, J. ;

Howlett, J. G. ;

Katova, T. ;

Kitakaze, M. ;

Ljungman, C. E. A. ;

Merkely, B. ;

Nicolau, J. C. ;

O'Meara, E. ;

Petrie, M. C. ;

Vinh, P. N. ;

Schou, M. ;

Tereshchenko, S. ;

Verma, S. ;

Held, C. ;

DeMets, D. L. ;

Docherty, K. F. ;

Jhund, P. S. ;

Bengtsson, O. ;

Sjostrand, M. ;

Langkilde, A. -M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :1995-2008

[7] The Combined Incremental Prognostic Value of LVEF, Late Gadolinium Enhancement, and Global Circumferential Strain Assessed by CMR [J].

Mordi, Ify ;

Bezerra, Hiram ;

Carrick, David ;

Tzemos, Nikolaos .

JACC-CARDIOVASCULAR IMAGING, 2015, 8 (05) :540-549

[8] LGE and NT-proBNP Identify Low Risk of Death or Arrhythmic Events in Patients With Primary Prevention ICDs [J].

Mordi, Ify ;

Jhund, Pardeep S. ;

Gardner, Roy S. ;

Payne, John ;

Carrick, David ;

Berry, Colin ;

Tzemos, Nikolaos .

JACC-CARDIOVASCULAR IMAGING, 2014, 7 (06) :561-569

[9] Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis [J].

Mudaliar, Sunder ;

Alloju, Sindura ;

Henry, Robert R. .

DIABETES CARE, 2016, 39 (07) :1115-1122

[10] Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes [J].

Packer, Milton .

DIABETES CARE, 2018, 41 (01) :11-13

← 1 2 →